1272010-17-9

Upstream product

• 57-41-0 phenythoin 
• 76-83-5 trityl chloride 

Downstream Products

• 1255933-44-8 1-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2,4-dione 
• 1255933-45-9 1-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropyl)-5,5-diphenylimidazolidine-2,4-dione 
• 1272010-26-0 1-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)-propyl)-5,5-diphenyl-3-tritylimidazolidine-2,4-dione 
• 1272010-29-3 1-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropyl)-5,5-diphenyl-3-tritylimidazolidine-2,4-dione 
• 1272010-03-3 1-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2,4-dione hydrochloride 
• 1272010-06-6 1-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2,4-dione hydrochloride 
• 1272010-09-9 1-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropyl)-5,5-diphenylimidazolidine-2,4-dione hydrochloride 
• 1272010-23-7 1-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl)-5,5-diphenyl-3-tritylimidazolidine-2,4-dione 
• 1272010-20-4 1-(oxiran-2-ylmethyl)-5,5-diphenyl-3-tritylimidazolidine-2,4-dione 
• 1350707-06-0 1-(4-bromobutyl)-5,5-diphenyl-3-tritylimidazolidine-2,4-dione 
• 1350707-09-3 5,5-diphenyl-1-(4-(4-phenylpiperazin-1-yl)butyl)-3-tritylimidazolidine-2,4-dione 
• 1350706-07-8 5,5-diphenyl-1-(4-(4-phenylpiperazin-1-yl)butyl)imidazolidine-2,4-dione 

Relevant academic research and scientific papers

Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to α1-adrenergic receptors among arylpiperazine derivatives of phenytoin

The study is focused on (2-alkoxy)phenylpiperazine derivatives of 1-(2-hydroxy-3-(4-arylpiperazin-1-yl)propyl)-5,5-diphenylimidazolidine-2, 4-dione with alkyl or ester substituents at N3 of hydantoin ring, as well as a new designed and synthesized series

Oligomer-containing hydantoin compounds

The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oli